North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group

 
back
4 Central nervous system
04-06 Domperidone and metoclopramide

Domperidone
Formulary

Domperidone (as Domperidone maleate) Tablet 10mg

The MHRA has advised that there is a small risk of serious ventricular arrhythmia and sudden cardiac death with domperidone.

MHRA advice: Domperidone- risk of cardiac side-effects (Dec 2014)

MHRA (Dec 2019): Domperidone is no longer licensed for use in children younger than 12 or those weighing less than 35 kg. 

Link  MHRA Drug Safety Guidance: Domperidone: risks of cardiac side effects
Link  MHRA Drug Safety Guidance: Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents
 

Green View adult BNF  View SPC online  View childrens BNF
Domperidone
Formulary
Domperidone Oral Suspension SF 1mg/ml
Domperidone (as Domperidone maleate) Tablet 10mg

Babies and children up to 18 years

MHRA (Dec 2019): Domperidone is no longer licensed for use in children younger than 12 or those weighing less than 35 kg. 

Link  MHRA Drug Safety Guidance: Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents
 

Amber View adult BNF  View SPC online  View childrens BNF
Metoclopramide Hydrochloride
Formulary

Metoclopramide Hydrochloride Tablet 10mg
Metoclopramide Hydrochloride Injection 10mg/2ml Amps

Standard release preparations only

MHRA/CHM advice—Metoclopramide: risk of neurological adverse effects—restricted dose and duration of use (August 2013)

Caution for <20 year olds. MHRA advises that length of treatment should be no longer than 5 days

Link  MHRA Guidance on Metoclopramide
 

Green View adult BNF  View SPC online  View childrens BNF